Novartis AG
NVS Real Time Price USD$NVS is featured in our Shelley Moore Capito strategy.
See All StrategiesRecent trades of NVS by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by NVS's directors and management
Government lobbying spending instances
-
$40,000 Feb 04, 2003 Issue: Agriculture
Estimated quarterly lobbying spending
NVS Revenue by Segment or Geography
No Revenue by Segment data for this ticker
No Revenue by Geography data for this ticker
New patents grants
-
Patent Title: Sacubitril calcium salts Oct. 17, 2023
-
Patent Title: Anti-cd40 antibodies for use in prevention of graft rejection Oct. 10, 2023
-
Patent Title: Antibodies to pmel17 and conjugates thereof Oct. 10, 2023
-
Patent Title: Compounds and compositions for treating conditions associated with nlrp activity Sep. 19, 2023
-
Patent Title: Dosage regimen of an s1p receptor modulator Sep. 19, 2023
-
Patent Title: Compounds and compositions for inducing chondrogenesis Sep. 12, 2023
-
Patent Title: Fatty acids and their use in conjugation to biomolecules Sep. 12, 2023
-
Patent Title: Compounds and compositions for treating solid tumors by intratumoral administration Sep. 12, 2023
-
Patent Title: Biomarkers predictive of cytokine release syndrome Sep. 05, 2023
-
Patent Title: Computer method and system for deriving cell-to-cell spatial proximities Sep. 05, 2023
-
Patent Title: Therapeutic regimen Aug. 29, 2023
-
Patent Title: Method of scoring a sample comprising tumor tissue Aug. 15, 2023
-
Patent Title: Methods of treating ophthalmic disorders Aug. 15, 2023
-
Patent Title: Compounds and compositions for treating conditions associated with nlrp activity Aug. 15, 2023
-
Patent Title: Uses of piperidinyl-indole derivatives Aug. 15, 2023
-
Patent Title: Sulphonamides and compositions thereof for treating conditions associated with nlrp activity Aug. 08, 2023
-
Patent Title: Cell bag rotator Aug. 08, 2023
-
Patent Title: Methods for treating hematologic cancers Jul. 25, 2023
-
Patent Title: Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof Jul. 25, 2023
-
Patent Title: Pyrazolyl derivatives useful as anti-cancer agents Jul. 18, 2023
-
Patent Title: Fgf21 mimetic antibodies and uses thereof Jul. 04, 2023
-
Patent Title: Engineered heterodimeric proteins Jun. 27, 2023
-
Patent Title: Multi-dose ocular fluid delivery system Jun. 20, 2023
-
Patent Title: Amino pyrimidine derivatives Jun. 13, 2023
-
Patent Title: 1,4-disubstituted pyridazine quinolne analogs there of and methods for treating smn-deficiency-related conditions Jun. 13, 2023
-
Patent Title: Carboxamide derivatives Jun. 13, 2023
-
Patent Title: Treatment of cancer using chimeric cd3 receptor proteins Jun. 06, 2023
-
Patent Title: Antiviral pyrazolopyridinone compounds Jun. 06, 2023
-
Patent Title: Crystalline forms of 5-bromo-2,6-di(1h-pyrazol-1- yl)pyrimidin-4-amine and new salts May. 23, 2023
-
Patent Title: Thienopyrimidinone nmda receptor modulators and uses thereof May. 16, 2023
-
Patent Title: Method for preparing a pharmaceutical product May. 09, 2023
-
Patent Title: Polyomavirus neutralizing antibodies May. 02, 2023
-
Patent Title: Anti-ccr7 antibody drug conjugates Apr. 25, 2023
-
Patent Title: 10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7h-pyrrolo[1′,2′:4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza Apr. 18, 2023
-
Patent Title: Solid forms comprising an oxime ether compound, compositions and methods of use thereof Apr. 18, 2023
-
Patent Title: Parenteral formulation comprising siponimod Apr. 18, 2023
-
Patent Title: Substituted pyrrolo[2,3-d]pyrimidines as bruton's tyrosine kinase inhibitors Mar. 28, 2023
-
Patent Title: Bcma chimeric antigen receptors and uses thereof Mar. 21, 2023
-
Patent Title: Injector device Mar. 21, 2023
-
Patent Title: Crystalline form of lnp023 Mar. 14, 2023
-
Patent Title: Compounds and compositions for the treatment of parasitic diseases Mar. 07, 2023
-
Patent Title: Compounds and compositions for treating conditions associated with nlrp activity Mar. 07, 2023
-
Patent Title: Specific sites for modifying antibodies to make immunoconjugates Mar. 07, 2023
-
Patent Title: Treatment of cancer using a cd123 chimeric antigen receptor Feb. 28, 2023
-
Patent Title: Pharmaceutical compositions of lipoic acid choline ester salts and methods of treatment using same Feb. 28, 2023
-
Patent Title: Regulatable chimeric antigen receptor Feb. 14, 2023
-
Patent Title: Stable and soluble antibodies inhibiting tnfα Feb. 14, 2023
-
Patent Title: Chemical process for preparing phenylpiperidinyl indole derivatives Feb. 14, 2023
-
Patent Title: 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof Jan. 31, 2023
-
Patent Title: Injection device and injection solution transferring system Jan. 17, 2023
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to NVS
Number of mentions of NVS in WallStreetBets Daily Discussion
Recent picks made for NVS stock on CNBC
ETFs with the largest estimated holdings in NVS
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view NVS Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.